Published in Mol Cell Endocrinol on June 30, 2003
The role of liver-derived insulin-like growth factor-I. Endocr Rev (2009) 1.87
Hormonal regulation of longevity in mammals. Ageing Res Rev (2007) 1.15
The emerging role of IGF-1 deficiency in cardiovascular aging: recent advances. J Gerontol A Biol Sci Med Sci (2012) 1.14
Hormonal control of aging in rodents: the somatotropic axis. Mol Cell Endocrinol (2008) 1.07
PTEN controls β-cell regeneration in aged mice by regulating cell cycle inhibitor p16ink4a. Aging Cell (2013) 0.92
Up-regulation of microRNA-190b plays a role for decreased IGF-1 that induces insulin resistance in human hepatocellular carcinoma. PLoS One (2014) 0.88
Activation of the Reg family genes by pancreatic-specific IGF-I gene deficiency and after streptozotocin-induced diabetes in mouse pancreas. Am J Physiol Endocrinol Metab (2006) 0.86
The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev (2006) 4.93
Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest (2002) 3.86
Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int (2008) 2.59
Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med (2004) 2.51
Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology (2004) 2.40
Minireview: IGF, Insulin, and Cancer. Endocrinology (2011) 2.16
Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res (2010) 2.13
Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest (2006) 2.03
Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab (2007) 2.02
The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem (2003) 1.99
Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res (2002) 1.96
Altered ovarian function affects skeletal homeostasis independent of the action of follicle-stimulating hormone. Endocrinology (2007) 1.94
Disruption of growth hormone receptor gene causes diminished pancreatic islet size and increased insulin sensitivity in mice. Am J Physiol Endocrinol Metab (2004) 1.92
Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem (2004) 1.91
The worldwide diabetes epidemic. Curr Opin Endocrinol Diabetes Obes (2012) 1.86
Growth retardation and premature aging phenotypes in mice with disruption of the SNF2-like gene, PASG. Genes Dev (2004) 1.84
Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest (2004) 1.82
Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. Endocrinology (2006) 1.71
The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab (2010) 1.67
Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol (2004) 1.67
Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis. J Hepatol (2013) 1.52
CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders. J Clin Invest (2016) 1.51
Obesity, type 2 diabetes, and cancer: the insulin and IGF connection. Endocr Relat Cancer (2012) 1.48
The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes. Diabetes Metab Res Rev (2014) 1.45
Increased tumor growth in mice with diet-induced obesity: impact of ovarian hormones. Endocrinology (2006) 1.44
Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res (2003) 1.44
The role of endocrine insulin-like growth factor-I and insulin in breast cancer. J Mammary Gland Biol Neoplasia (2008) 1.40
The link between the metabolic syndrome and cancer. Int J Biol Sci (2011) 1.37
Pancreatic-specific inactivation of IGF-I gene causes enlarged pancreatic islets and significant resistance to diabetes. Diabetes (2004) 1.36
Biological effects of growth hormone on carbohydrate and lipid metabolism. Growth Horm IGF Res (2009) 1.35
Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann N Y Acad Sci (2011) 1.34
Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy. Mol Endocrinol (2008) 1.33
Partial rescue of the Hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) expression. Mol Endocrinol (2002) 1.32
Insulin resistance as the underlying cause for the metabolic syndrome. Med Clin North Am (2007) 1.29
Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes. Endocrinology (2005) 1.29
Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes (2009) 1.28
Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes (2003) 1.28
Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjögren's syndrome. Hum Gene Ther (2003) 1.28
PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene (2004) 1.27
Insulin-like growth factor 1 receptor signaling regulates skin development and inhibits skin keratinocyte differentiation. Mol Cell Biol (2006) 1.26
Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage. J Biol Chem (2002) 1.26
Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. FASEB J (2008) 1.23
Increased P85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess. J Biol Chem (2005) 1.22
Elevated levels of insulin-like growth factor (IGF)-I in serum rescue the severe growth retardation of IGF-I null mice. Endocrinology (2009) 1.21
Growth hormone regulates the balance between bone formation and bone marrow adiposity. J Bone Miner Res (2010) 1.20
Targeted loss of GHR signaling in mouse skeletal muscle protects against high-fat diet-induced metabolic deterioration. Diabetes (2012) 1.18
Effects of liver-derived insulin-like growth factor I on bone metabolism in mice. J Bone Miner Res (2002) 1.18
TDAG51 mediates the effects of insulin-like growth factor I (IGF-I) on cell survival. J Biol Chem (2004) 1.17
PTEN overexpression suppresses proliferation and differentiation and enhances apoptosis of the mouse mammary epithelium. J Clin Invest (2002) 1.16
Type 2 diabetes and cancer: what is the connection? Mt Sinai J Med (2010) 1.16
Absence of the full-length breast cancer-associated gene-1 leads to increased expression of insulin-like growth factor signaling axis members. Cancer Res (2006) 1.15
Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences. Horm Res (2009) 1.13
Defects in mesenchymal stem cell self-renewal and cell fate determination lead to an osteopenic phenotype in Bmi-1 null mice. J Bone Miner Res (2010) 1.12
Growth hormone receptor regulates β cell hyperplasia and glucose-stimulated insulin secretion in obese mice. J Clin Invest (2011) 1.12
Elevated serum levels of IGF-1 are sufficient to establish normal body size and skeletal properties even in the absence of tissue IGF-1. J Bone Miner Res (2010) 1.12
Muscle-specific overexpression of CD36 reverses the insulin resistance and diabetes of MKR mice. Endocrinology (2004) 1.10
Tamoxifen attenuates inflammatory-mediated damage and improves functional outcome after spinal cord injury in rats. J Neurochem (2009) 1.08
Insulin, insulin resistance, obesity, and cancer. Curr Diab Rep (2010) 1.07
Insulin-like growth factor-I regulates the liver microenvironment in obese mice and promotes liver metastasis. Cancer Res (2010) 1.07
Critical prosurvival roles for C/EBP beta and insulin-like growth factor I in macrophage tumor cells. Mol Cell Biol (2004) 1.07
Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell. Endocrinology (2008) 1.06
Genetic models show that parathyroid hormone and 1,25-dihydroxyvitamin D3 play distinct and synergistic roles in postnatal mineral ion homeostasis and skeletal development. Hum Mol Genet (2005) 1.04
Peroxisome proliferator-activated receptor-alpha deficiency does not alter insulin sensitivity in mice maintained on regular or high-fat diet: hyperinsulinemic-euglycemic clamp studies. Endocrinology (2003) 1.04
Serum IGF-1 affects skeletal acquisition in a temporal and compartment-specific manner. PLoS One (2011) 1.04
Parathyroid hormone-related peptide interacts with bone morphogenetic protein 2 to increase osteoblastogenesis and decrease adipogenesis in pluripotent C3H10T 1/2 mesenchymal cells. Endocrinology (2003) 1.04
Energy-preserving effects of IGF-1 antagonize starvation-induced cardiac autophagy. Cardiovasc Res (2011) 1.03
Type 2 diabetic mice demonstrate slender long bones with increased fragility secondary to increased osteoclastogenesis. Bone (2008) 1.03
Overexpression of the tumor suppressor gene phosphatase and tensin homologue partially inhibits wnt-1-induced mammary tumorigenesis. Cancer Res (2005) 1.02
Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Res (2012) 1.01
Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor. Diabetes (2013) 1.01
Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression. Cancer Res (2008) 1.01
High-efficient FLPo deleter mice in C57BL/6J background. PLoS One (2009) 1.01
The metabolic syndrome--from insulin resistance to obesity and diabetes. Endocrinol Metab Clin North Am (2008) 1.00
Reduced susceptibility to two-stage skin carcinogenesis in mice with low circulating insulin-like growth factor I levels. Cancer Res (2008) 1.00
Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer. Diabetes Care (2013) 1.00
A familial insulin-like growth factor-I receptor mutant leads to short stature: clinical and biochemical characterization. J Clin Endocrinol Metab (2007) 0.99